ArticleImmunity2021
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 135 citations in OpenAlex.
- Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.Nature communications · 2026Article
- The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma.Journal of advanced research · 2026Article
- Article
- Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annual review of cancer biology · 2026Article
- Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Machine learning identified extrachromosomal DNA-related 12 gene signatures to predict cancer immunotherapy response.Cancer cell international · 2025Article
- Immunometabolic Dysregulation in B-Cell Acute Lymphoblastic Leukemia Revealed by Single-Cell RNA Sequencing: Perspectives on Subtypes and Potential Therapeutic Targets.International journal of molecular sciences · 2025Article
- Personalizing DNA Cancer Vaccines.Journal of personalized medicine · 2025Review
- Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods.Cancer immunology research · 2025Article
- Nuclear glycine decarboxylase suppresses STAT1-dependent MHC-I and promotes cancer immune evasion.The EMBO journal · 2025Article
- Article
- HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Mechanism by which SUGT1 downregulates FH to promote proliferation and migration in serous ovarian cancer.Journal of ovarian research · 2025Article
- Comparison of local effects and systemic T-cell responses in patients with breast cancer treated by radiofrequency ablation versus microwave ablation.Cancer cell international · 2025Article
- Article
- Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.Nature cancer · 2025Article
- Whole-Genome Sequencing Reveals the Role of Cis-Regulatory Elements and eQTL/sQTL in the Adaptive Selection of Hubei Indigenous Cattle.Animals : an open access journal from MDPI · 2025Article
- Massively parallel interrogation of human functional variants modulating cancer immunosurveillance.Signal transduction and targeted therapy · 2025Article
- EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.Cancer cell · 2025Article
- Evolutionary trajectories of immune escape across cancers.bioRxiv : the preprint server for biology · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Devin DershLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: devin.dersh@nih.gov.
James D PhelanLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Megan E GuminaLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Boya WangLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jesse H ArbuckleLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jaroslav HollyLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Rigel J KishtonSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA.
Tovah E MarkowitzNIAID Collaborative Bioinformatics Resource, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Mina O SeedhomLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Nathan FridlyandLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
George W WrightBiometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Da Wei HuangLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Michele CeribelliDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Justin B LackNIAID Collaborative Bioinformatics Resource, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Nicholas P RestifoSurgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA.
Thomas M KristieLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jonathan W YewdellLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: jyewdell@niaid.nih.gov.
National Cancer Institute · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USNational Center for Advancing Translational Sciences · US
Funding
Oncogenic mechanisms and molecular targets in lymphomaZIABC011008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0MTranslation in ImmunityZIAAI001210 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI YEWDELL, JONATHAN W · 2016 to 2025
$12.5MHTS enabled examination of drug combinationsZIATR000047 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI THOMAS, CRAIG · 2015 to 2025
$7.1MIntramural NIH HHS Z99 NH999999
Abstract
Tumors frequently subvert major histocompatibility complex class I (MHC-I) peptide presentation to evade CD8
Indexed as
Biomarkers, TumorB-LymphocytesCarcinogenesisCell Cycle ProteinsCell DifferentiationCell LineageCell Line, TumorEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticGenetic TestingGenome-Wide Association StudyHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansImmunologic SurveillanceBiomarkers, TumorCell Cycle ProteinsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensSUGT1 protein, humanantigen presentationdiffuse large B cell lymphomaEZH2HLA class IimmunoevasionimmunotherapyMHC class IMHC class IISUGT1thymidylate synthase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.